Author (Enrollment years) | N | MR prevalence (%) | Moderate or severe MR (%) | Treatment strategy | STEMI | F/U | Death (%) | Other | Mitral surgical correction (%) |
---|---|---|---|---|---|---|---|---|---|
Barzilai et al. [31] (1985-1986) | 59 | 39 | NR | NR | 59% | 14 m | MR (+): 48%, MR (0): 11% | NR | NR |
Bursi et al. [2] (1988-1998) | 773 | 50 | 12 | NR | 59% | 5 y | None: 28%, Mild: 38%, M-S: 60% | CHF Adm | NR |
None: 16%, Mild: 26%, M-S: 65% | |||||||||
Grigioni et al. [6] (1990-1997) | 303 | 64 | NR | NR | 100% | 5 y | MR (+): 62%, MR (0): 39% | Card Death | NR |
MR (+): 50%, MR (0): 30% | |||||||||
Amigoni et al. (Valiant study) [1] (1998-2001) | 496 | 53 | 13 | Thrombolytic (40%), PCI (19%) | 63% | 20 m | None: 10%, Mild: 21%, M-S: 30% | NR | NR |
Feinberg et al. [5] (1996) | 417 | 35 | 6 | Thrombolytic (42%), PTCA / CABG (41%) | 100% | 1 y | None: 4.8%, Mild: 12.4%, M-S: 24% | NR | NR |
Van Dantzig et al. [33] (1991-1993) | 188 | NR | 13 | Thrombolytic (55%) | 62% | NR | NR | NR | NR |
Leor et al. [32] (N/A) | 104 | 33 | 11 | Thrombolytic (100%) | 100% | 1 m | NR | NR | NR |
Aronson et al. [30] (2000-2005) | 1190 | 46 | 6 | PCI (30%) | 100% | 2 y | None: 8%, Mild: 15%, M-S: 38% | CHF Adm | NR |
None: 0.6%, Mild: 3.6%, M-S: 4% | |||||||||
Barra et al. [16] (2006-2008) | 796 | 45 | 15 | PCI (56%) | 45% | 2 y | None: 12%, Mild: 22%, M-S: 39% | CHF Adm | NR |
None: 11%, Mild: 24%, M-S: 20% | |||||||||
Chung et al. [4] (2000-2002) | 519 | 56 | 15 | PCI (81%) | 86% | 6 m | None - Mild: 10%, M-S: 19% | NR | NR |
Chua et al. [3] (2000-2004) | 318 | 17 | NR | PCI (100%) | 100% | 7 y | MR (+): 49%, MR (0): 26% | NR | NR |
Wita et al. [15] (N/A) | 83 | 42 | NR | PCI (100%) | 100% | 6 m | NR | NR | NR |
Uddin et al. [18] (2003-2007) | 888 | 47 | 11 | PCI (100%) | 100% | 5 y | None: 13%, Mild: 18%, M-S: 34% | NR | None: 0%, Mild: 0%, M-S: 4% |
MacHaalany et al. (2006–2012) | 174 | 44 | 11 | PCI (100%) | 100% | 1 y | None: 0%, Mild: 2%, M-S: 5% | CHF Adm | None: 0%, Mild: 0%, M-S: 26% |
None: 0%, Mild: 2%, M-S: 5% |